Introduction
Several clinical studies have indicated that smokers experience greater postoperative pain and require more opioid analgesics than nonsmokers [1] [2] [3] . It has been reported that the postoperative dosage of opioids correlates with the degree of nicotine dependence in patients undergoing anterior cervical corpectomy [4] . Therefore, current smokers scheduled for surgery are required to stop smoking before surgery. However, smokers deprived of nicotine require more opioid analgesics [5] . We have previously found that nicotine withdrawal induces hyperalgesia in rats [6] . The mechanisms underlying the effect of nicotine on pain are not yet fully understood.
It is well known that tissue injury-induced hypersensitivity is caused peripherally by the sensitization of primary afferent nerve fibers and centrally via modulation of nociceptive transmission at the spinal cord level [7, 8] .
Enhanced excitability of spinal cord neurons contributes to central pain sensitivity [7] .
The release of brain-derived neurotrophic factor (BDNF) from microglia has been found to control neuronal excitability by causing disinhibition [9] . It has been reported that nicotine receptors contribute to microglial activation, which enhances release of BDNF [9, 10] . Gamma-aminobutyric acid (GABA) is known to mediate neuronal inhibition, which depends on intracellular chloride (Cl -) concentrations [11] . Cation-chloride cotransporters (CCC) play an important role in the maintenance of intracellular is important for GABA-induced neuronal hyperpolarization [12] . It has been reported that downregulation of KCC2 reduces GABAinduced hyperpolarization, and thus increases neuronal excitability and subsequently reduces the injury-induced pain threshold [13, 14] . However, it remains unclear whether KCC2
is involved in nicotine withdrawal-induced hyperalgesia.
The expression and function of KCC2 is regulated by many signaling pathways such as BDNF signaling [15] . BDNF is released from microglia [16] and acts on the tropomyosin receptor kinase (Trk) in neurons [17] . Intrathecal injection of antibodies against Trk upregulates the expression of KCC2 in the spinal cord [18] , suggesting that Trk signaling activation inhibits KCC2 expression. In animal models of inflammation-induced pain [18] , neuropathic pain [19] , and opiate-induced hyperalgesia [20] , BDNF has been found to downregulate KCC2 expression via activation of Trk receptors.
However, the involvement of BDNF/Trk/KCC2 signaling in nicotine withdrawal-induced hyperalgesia remains unclear.
In this study, using intrathecal injection of the Trk antagonist K252a, we investigated the effect of BDNF/Trk signaling on the expression of KCC2 in a rat model of nicotine withdrawal.
The purpose of this investigation was to study the effect of BDNF in nicotine-induced hyperalgesia, and to explore the role of the BDNF/Trk/KCC2 signaling pathway in nicotine withdrawal-induced hyperalgesia. To investigate the effect of brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase (Trk) on potassium chloride cotransporter 2 (KCC2) in rats following nicotine withdrawal and the roles played by BDNF/Trk/KCC2 pathway in nicotine withdrawal-induced hyperalgesia. Methods: Seventy-eight rats were randomly assigned to five groups: control group (n = 12) without any treatment, normal saline group (NS group, n = 12) and nicotine withdrawal group (NW group, n = 30) receiving a subcutaneous injection of saline or nicotine for 7 days, respectively. The NW + dimethyl sulfoxide (DMSO) (n = 12) and NW+ Trk antagonist K252a groups (n = 12) received an intrathecal injection of DMSO (10 μl) and K252a (10 μg/10 μl) for 3 days after nicotine withdrawal, respectively. Nicotine withdrawal was precipitated by subcutaneous injection of nonselective and noncompetitive antagonist of nicotinic acetylcholine receptors mecamylamine. Pain was tested using thermal withdrawal latency (TWL). A Western blot was used to examine the expression of BDNF and KCC2. Results: The TWL was significantly decreased in NW group relative to control and NS groups (P < 0.01). Compared with the NW group, the NW+K252a group manifested a significantly higher latency (P < 0.01). The BDNF expression was increased and KCC2 was decreased in NW group compared with the control group (P < 0.01). K252a reduced KCC2 downregulation. Conclusion: BDNF/Trk signaling may contribute to nicotine withdrawal-induced hyperalgesia via downregulation of KCC2. 
Intrathecal injection
Rats in the NW+DMSO and NW+K252a groups were injected intrathecally with DMSO and K252a, respectively, as previously described [21] . The rats were anesthetized by inhalation of ethyl ether. The rats were held securely in one hand by the pelvic girdle followed 
Statistical analysis

results
K252a reduced nicotine withdrawalinduced hyperalgesia in rats
There were no significant differences in the TWL between control and NS groups. Compared with the control group, the TWL significantly decreased from 1 to 7 days after nicotine withdrawal in the NW group (P < 0.01, Fig. 1 (Fig. 4) .
Discussion
In the present study, we found that the TWL significantly decreased from days 1 through KCC2 is necessary for GABA-inhibitory function in the central nervous system. KCC2
has been reported to modulate pain sensation in the spinal cord [13, 14, 22] . Peripheral nerve injury reduced KCC2 expression in the spinal dorsal horn, leading to an increase in the intracellular Cl -concentration, resulting in enhanced neuronal excitability via reduction of GABA inhibition [22] . Increased neuronal excitability due to KCC2 downregulation reduced the pain threshold, and thus induced pain [13, 14] . In addition, it has been reported that nicotine promoted the release of GABA via activation of nicotine receptors [23, 24] .
Nicotinic receptors play an important role in the switch from excitatory to inhibitory function of GABA during early neuronal development [25] .
The increased permeability of alpha-7-nicotinic acetyl cholinergic receptors (α7-nAChR) to Ca Nicotine exerts analgesic effects via nicotinic acetylcholine receptors (nAChR) centrally and peripherally [27] . The nAChR consist of five transmembrane proteins, and are permeable to cations such as Na + , Ca 2+ and K + [28, 29] .
The α7-nAChR are expressed in the microglia of the central nervous system, and mediate the "cholinergic anti-inflammatory pathway"
by inhibiting the release of proinflammatory factors [30] . In contrast, nicotine withdrawal promotes the release of proinflammatory factors via disinhibition of the cholinergic antiinflammatory pathway [31] . Previous studies have shown that nicotine withdrawal activates microglia in rats. BDNF is released from microglia [16] , and acts as an endogenous modulator of nociceptive response in the spinal cord [32] . In the present study, we found that the expression of BDNF was increased in the spinal cord after nicotine withdrawal, further suggesting that BDNF contributes to nicotine withdrawal- K252a, a selective Trk inhibitor [35] , blocks this effect [22] . K252a inhibits Trk receptors including TrkA, TrkB, and TrkC. Neurotrophins including nerve growth factor (NGF), BDNF, neurotrophic factor 3 (NT-3), and neurotrophic factor 4 (NT-4) bind to these receptors with high affinity. It has been reported that NT-3 [36] and NT-4 [37] are not involved in the pain pathway. In contrast, NGF, which primarily binds to TrkA receptors, plays an important role in inflammatory pain in the peripheral nervous system, and BDNF, which mainly acts on the TrkB receptors, is mediating hyperalgesia in the central nervous system [38] . Both in vivo and in vitro experiments have shown that activation of the BDNF-Trk pathway [39] leads to downregulation of KCC2 expression, but NGF has no effect on KCC2 expression [40] . In the present study, we found that intrathecal 
